FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238792593> ?p ?o ?g. }

• W4238792593 endingPage "S11" @default.
• W4238792593 startingPage "S11" @default.
• W4238792593 abstract "Abstract Introduction Ontamalimab is a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1 in development for the induction and maintenance of clinical remission in patients with ulcerative colitis (UC). This study aimed to assess the long-term pharmacokinetics (PK) of ontamalimab in patients with UC, and the effects of concomitant medications on PK parameters. Methods A 12-week induction study (TURANDOT; NCT01620255) was performed to assess the PK, efficacy and safety of ontamalimab (7.5, 22.5, 75 and 225 mg subcutaneous [s.c.] every four weeks [Q4W]) in patients with UC. Individuals who completed the induction study were eligible for enrollment in an open-label extension (OLE) study (TURANDOT II; NCT01771809) to assess the long-term PK, efficacy and safety of ontamalimab (75 or 225 mg s.c. Q4W up to week 72). Population PK analyses were performed using nonlinear mixed-effects modelling. Exposure-response analyses were performed to assess the relationships between minimum concentration (Cmin,ss) of ontamalimab and clinical response, clinical remission and mucosal healing. The effect of concomitant treatments (used for ≥20% of treatment duration) on PK parameters was also evaluated. Results The PK population included 130 (39.8%) women and 197 (60.2%) men, of median age of 40 years. A 1-compartment model with linear elimination adequately described the PK of ontamalimab. Population estimates of apparent clearance (CL/F) and volume of distribution (V/F) were 0.00917 L/h (0.22 L/day) and 7.44 L, respectively. Albumin had a significant effect on the variability of CL/F. Individuals with albumin levels of 30 g/L and 47 g/L are expected to have CL/F values 44% higher and 23% lower, respectively, than a typical patient with an albumin level of 39 g/L. Anti-inflammatory agents affected CL/F, such that CL/F is expected to be 14% higher in patients receiving than not receiving these agents. Other medications including immunosuppressants, steroids and treatments for peptic ulcers and gastroesophageal reflux disease had no effect on CL/F. Weight was the only covariate that significantly affected V/F. The half-life of ontamalimab was 23.4 days. Concentrations of ontamalimab over 72 weeks in the OLE study were consistent with those observed in the 12-week induction study. Ontamalimab Cmin,ss was related to efficacy, such that at week 16 (week 28 in total including induction), patients with higher Cmin,ss values were more likely to have clinical response, clinical remission and mucosal healing than those with lower Cmin,ss. Conclusion The exposure to ontamalimab was sustained following prolonged treatment in patients with UC for up to 72 weeks. Higher ontamalimab exposure was associated with a higher probability of clinical response." @default.
• W4238792593 created "2022-05-12" @default.
• W4238792593 creator A5027362721 @default.
• W4238792593 creator A5029667848 @default.
• W4238792593 creator A5050721782 @default.
• W4238792593 creator A5059338966 @default.
• W4238792593 creator A5071073078 @default.
• W4238792593 date "2020-01-01" @default.
• W4238792593 modified "2023-10-16" @default.
• W4238792593 title "P069 ONTAMALIMAB, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1, PROVIDES SUSTAINED EXPOSURE FOLLOWING LONG-TERM TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS" @default.
• W4238792593 doi "https://doi.org/10.1093/ibd/zaa010.026" @default.
• W4238792593 hasPublicationYear "2020" @default.
• W4238792593 type Work @default.
• W4238792593 citedByCount "0" @default.
• W4238792593 crossrefType "journal-article" @default.
• W4238792593 hasAuthorship W4238792593A5027362721 @default.
• W4238792593 hasAuthorship W4238792593A5029667848 @default.
• W4238792593 hasAuthorship W4238792593A5050721782 @default.
• W4238792593 hasAuthorship W4238792593A5059338966 @default.
• W4238792593 hasAuthorship W4238792593A5071073078 @default.
• W4238792593 hasBestOaLocation W42387925931 @default.
• W4238792593 hasConcept C112705442 @default.
• W4238792593 hasConcept C126322002 @default.
• W4238792593 hasConcept C139254425 @default.
• W4238792593 hasConcept C159654299 @default.
• W4238792593 hasConcept C170493617 @default.
• W4238792593 hasConcept C195687474 @default.
• W4238792593 hasConcept C203014093 @default.
• W4238792593 hasConcept C22979827 @default.
• W4238792593 hasConcept C2776207728 @default.
• W4238792593 hasConcept C2778335254 @default.
• W4238792593 hasConcept C2779134260 @default.
• W4238792593 hasConcept C2779384505 @default.
• W4238792593 hasConcept C2780479503 @default.
• W4238792593 hasConcept C2908647359 @default.
• W4238792593 hasConcept C4175445 @default.
• W4238792593 hasConcept C542903549 @default.
• W4238792593 hasConcept C71924100 @default.
• W4238792593 hasConcept C90924648 @default.
• W4238792593 hasConcept C98274493 @default.
• W4238792593 hasConcept C99454951 @default.
• W4238792593 hasConceptScore W4238792593C112705442 @default.
• W4238792593 hasConceptScore W4238792593C126322002 @default.
• W4238792593 hasConceptScore W4238792593C139254425 @default.
• W4238792593 hasConceptScore W4238792593C159654299 @default.
• W4238792593 hasConceptScore W4238792593C170493617 @default.
• W4238792593 hasConceptScore W4238792593C195687474 @default.
• W4238792593 hasConceptScore W4238792593C203014093 @default.
• W4238792593 hasConceptScore W4238792593C22979827 @default.
• W4238792593 hasConceptScore W4238792593C2776207728 @default.
• W4238792593 hasConceptScore W4238792593C2778335254 @default.
• W4238792593 hasConceptScore W4238792593C2779134260 @default.
• W4238792593 hasConceptScore W4238792593C2779384505 @default.
• W4238792593 hasConceptScore W4238792593C2780479503 @default.
• W4238792593 hasConceptScore W4238792593C2908647359 @default.
• W4238792593 hasConceptScore W4238792593C4175445 @default.
• W4238792593 hasConceptScore W4238792593C542903549 @default.
• W4238792593 hasConceptScore W4238792593C71924100 @default.
• W4238792593 hasConceptScore W4238792593C90924648 @default.
• W4238792593 hasConceptScore W4238792593C98274493 @default.
• W4238792593 hasConceptScore W4238792593C99454951 @default.
• W4238792593 hasIssue "Supplement_1" @default.
• W4238792593 hasLocation W42387925931 @default.
• W4238792593 hasOpenAccess W4238792593 @default.
• W4238792593 hasPrimaryLocation W42387925931 @default.
• W4238792593 hasRelatedWork W2037500960 @default.
• W4238792593 hasRelatedWork W2085427404 @default.
• W4238792593 hasRelatedWork W2294498517 @default.
• W4238792593 hasRelatedWork W2760563315 @default.
• W4238792593 hasRelatedWork W2794344940 @default.
• W4238792593 hasRelatedWork W2797809097 @default.
• W4238792593 hasRelatedWork W2904897913 @default.
• W4238792593 hasRelatedWork W4206120169 @default.
• W4238792593 hasRelatedWork W4238792593 @default.
• W4238792593 hasRelatedWork W4243764721 @default.
• W4238792593 hasVolume "26" @default.
• W4238792593 isParatext "false" @default.
• W4238792593 isRetracted "false" @default.
• W4238792593 workType "article" @default.